Gilead reveals positive results for domvanalimab
Study uses carious drug combinations to increase survival among lung cancer patients
Read More
Tag: domvanalimab
Arcus, Gilead prep Phase III studies of anti-TIGIT domvanalimab
Preparations come on the heels of positive results from the Phase II ARC-7 study
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
